Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Matrixyl 3000
Overview
Matrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The formulation is designed to synergistically promote collagen and fibronectin synthesis while reducing interleukin-6 mediated inflammation in dermal fibroblasts.
Mechanism of Action
Both peptides carry palmitic acid for enhanced lipid solubility and stratum corneum permeation.
Research Summary & Key Findings
Preclinical fibroblast assays have shown that the combination upregulates matrix protein gene expression and reduces IL-6 secretion in models of cellular senescence. Industry-sponsored clinical trials have reported reductions in wrinkle surface area and improved dermal density via ultrasound imaging after 8 to 12 weeks of topical application. Independent replication and publication in indexed dermatology journals remain limited.
Clinical Status
Matrixyl 3000 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Matrixyl 3000"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Matrixyl 3000"
Registered interventional and observational studies, including status and phase.
- PubChem: "Matrixyl 3000"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Dermatology
Afamelanotide (Scenesse)
FDA ApprovedA synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine a...
View detailsArgireline (Acetyl Hexapeptide-8)
InvestigationalArgireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter...
View detailsMatrixyl (Palmitoyl Pentapeptide-4)
InvestigationalMatrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety t...
View detailsMatrixyl Synthe'6 (Palmitoyl Tripeptide-38)
InvestigationalPalmitoyl tripeptide-38 is a synthetic lipopeptide designed to stimulate synthesis of six major constituents of the derm...
View detailsNo lawful pathway today
Matrixyl 3000 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.